Compare MPU & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPU | PRPO |
|---|---|---|
| Founded | 1989 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 44.4M |
| IPO Year | 2023 | 2000 |
| Metric | MPU | PRPO |
|---|---|---|
| Price | $0.73 | $29.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.1K | 12.0K |
| Earning Date | 03-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.57 | $5.21 |
| 52 Week High | $4.44 | $29.53 |
| Indicator | MPU | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 59.48 |
| Support Level | $0.72 | $22.96 |
| Resistance Level | $0.81 | $28.76 |
| Average True Range (ATR) | 0.04 | 1.73 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 53.54 | 82.12 |
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.